Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Imdusiran · AB-729

Oligonucleotide (siRNA) · Gene silencing: Hepatitis B virus · developed by Arbutus Biopharma

Phase 2 Most advanced trial

ABUS Developer

4 Registered trials

What is Imdusiran?

Imdusiran (AB-729) is a small interfering RNA (siRNA) inhibitor of hepatitis B virus (HBV), given as a subcutaneous injection once every 8 weeks. It is studied in chronic hepatitis B.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AB-729
Drug type: Oligonucleotide (siRNA)
Targets: Hepatitis B virus
Mechanism: Gene silencing: Hepatitis B virus
Therapy area: Gastroenterology, Infectious disease
Developer: Arbutus Biopharma Corporation (ABUS)
Also in trials of: ASMB
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 256UZ34AF2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06154278	Phase 2	Chronic Hepatitis B	Recruiting	ABUS
NCT06245291	Phase 2	Hepatitis B, Chronic	Withdrawn	ABUS
NCT04980482	Phase 2	Chronic Hepatitis b	Completed	ABUS
NCT04820686	Phase 2	Chronic Hepatitis B	Terminated	ASMB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Hepatitis BHepatitis B, Chronic

More from Arbutus Biopharma

AB-836 Phase 1 ARB-001467 Phase 2 Peg-IFNα-2a Phase 2 PRO-040201 Phase 1 TKM-100201 Phase 1 TKM-100802 Phase 1 TKM-PLK1 Phase 1/2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ABUS page.

Follow ABUS, the company behind Imdusiran

See ABUS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABUS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z